111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.
about
Clinical molecular imaging with radiotracers: current statusNeuroendocrine tumours of the head and neck: anatomical, functional and molecular imaging and contemporary management.Carotid body tumors: radioguided surgical approachRational approach to select small peptide molecular probes labeled with fluorescent cyanine dyes for in vivo optical imaging.Current approaches and recent developments in the management of head and neck paragangliomas.Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphyDiagnostic Performance of (68)Ga-DOTATATE PET/CT, (18)F-FDG PET/CT and (131)I-MIBG Scintigraphy in Mapping Metastatic Pheochromocytoma and Paraganglioma.The Challenges of Treating Paraganglioma Patients with (177)Lu-DOTATATE PRRT: Catecholamine Crises, Tumor Lysis Syndrome and the Need for Modification of Treatment ProtocolsPheochromocytoma and paraganglioma: current functional and future molecular imaging.Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma.68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRIEctopic acromegaly due to growth hormone releasing hormone.Current and future trends in the anatomical and functional imaging of head and neck paragangliomas.Molecular imaging of neuroendocrine tumorsSomatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implicationsHead and neck paragangliomas.⁶⁸Ga-labelled peptides in the management of neuroectodermal tumours.The incremental benefit of functional imaging in pheochromocytoma/paraganglioma: a systematic review.The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.Delayed intracranial and bony metastasis of paragangliomaRetroperitoneal paraganglioma manifesting as paralytic ileus: a case reportCorrelation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.Sporadic or familial head neck paragangliomas enrolled in a single center: clinical presentation and genotype/phenotype correlations.Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas.A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
P2860
Q26994741-E9C3862F-8C7B-47DD-BD11-F4BABFFA6B9FQ30412504-C97D345F-A748-4E5D-834D-545057C8EA3DQ33555883-C04DDD8C-B1E0-4703-98BB-2578A14EBC01Q33823047-A1D499DE-A5AD-4323-9EB9-B1EC0C60CD2AQ34204524-641DE6A8-9621-424A-AB1B-C37EA9DBBC3BQ35198539-4533AC99-153F-4AA6-B036-7969475B2E2BQ35724965-EB069210-E964-4E4A-A9CC-57E5104D895FQ35941125-59E8A5E1-5799-46CB-BAD1-FA69C5655903Q35972320-2F705026-6F3E-4F62-B23A-BE1C45F8D320Q36152379-C45DF963-3C59-40FE-A484-57E3EA2207F2Q36467134-532C7850-4CC4-4A5D-92D8-1984F7FB2006Q36467722-DF6BF15F-1631-415E-B5F1-C772EA7C91ACQ36535747-E878CE7B-9AC4-4ACC-8415-419B0EE267BCQ36557139-1FFC6883-4C93-4CB4-8773-999068BAD6EEQ37220182-DBD11273-2FFC-41B7-956A-3AB216AF6EFFQ37730951-3FC46E60-7713-4928-9747-482D73175F0FQ37772579-00F3ADF3-A5A9-4BF3-A40F-C7CC129FC28DQ37934784-0D129BDF-8C03-4392-B5C8-82AEEEB7F5C2Q37990398-21B1CB62-F398-4C21-ABE4-70F538C03137Q38348673-1E457149-115C-41F3-9350-214FE8A3001DQ38478344-AE4D44ED-EE4B-4A8A-B948-7CFA1C8B33DFQ40347934-DD5BD51E-C0B2-466B-92A4-F706D5C7442DQ42231361-A025D9A2-0928-4325-B7BA-E1206A5F19D8Q42282631-2E9EC73A-A93B-4230-B45D-D81BD28F67D4Q43376054-40EBB315-D1A3-4169-BC14-2147B84019E1Q44557934-8C67DFAC-EB0B-44A1-8443-B0696EB0A79AQ44951490-32A69A2C-8505-4F4E-B6BD-60A428183DADQ47108225-E09493D3-F8C4-493E-B7DC-120969858547Q53094166-F9BB4427-8A34-48E8-985D-A863BDB16019
P2860
111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
111In-octreotide is superior t ...... head and neck paragangliomas.
@en
111In-octreotide is superior t ...... head and neck paragangliomas.
@nl
type
label
111In-octreotide is superior t ...... head and neck paragangliomas.
@en
111In-octreotide is superior t ...... head and neck paragangliomas.
@nl
prefLabel
111In-octreotide is superior t ...... head and neck paragangliomas.
@en
111In-octreotide is superior t ...... head and neck paragangliomas.
@nl
P2093
P1476
111In-octreotide is superior t ...... f head and neck paragangliomas
@en
P2093
Frans Albers
Ido P Kema
Michiel N Kerstens
Pieter L Jager
Robin P F Dullaart
P304
P356
10.2967/JNUMED.107.047738
P407
P577
2008-07-16T00:00:00Z